Niagen Bioscience, Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
NAGE Nasdaq 2840 www.niagenbioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Niagen Bioscience, Inc.

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence - Aug 6th, 2026 6:34 am
Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value - Aug 6th, 2026 12:10 am
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ... - Aug 4th, 2026 11:04 pm
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates - Aug 4th, 2026 3:40 pm
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results - Aug 4th, 2026 2:02 pm
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 - Aug 3rd, 2026 6:32 am
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging - Jul 28th, 2026 6:32 am
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference - Jul 27th, 2026 6:32 am
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Jul 21st, 2026 6:32 am
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research - Jul 16th, 2026 6:32 am
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) - Jul 13th, 2026 6:32 am
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026 - Jul 9th, 2026 6:32 am
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases - Jul 8th, 2026 6:32 am
Implied Volatility Surging for Niagen Bioscience Stock Options - Jul 6th, 2026 9:15 am
Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications - Jun 19th, 2026 12:20 pm
Niagen Bioscience (NAGE) Stock Sees Split Analyst Revisions As Price Targets Fall - Jun 17th, 2026 7:12 am
Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program - Jun 4th, 2026 9:14 pm
How The Niagen Bioscience (NAGE) Investment Story Is Evolving Without New Analyst Signals - Jun 2nd, 2026 9:10 am
3 Growth Companies With High Insider Ownership And 15% Revenue Growth - May 22nd, 2026 5:35 am
How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower - May 15th, 2026 6:21 pm